Chloroquine Alleviates Atherosclerosis by Modulating Regulatory T Cells Through the ATM/AMPK/mTOR Signaling Pathway in ApoE ^−/− Mice

Abstract

Background Clinical observation suggests the atheroprotective effect of chloroquine and its derivatives, while its mechanism remains unclear. This study aimed to observe the protective effect of chloroquine against atherosclerosis and explore the underlying mechanism.

Methods Ataxia telangiectasia mutated (ATM) wild-type or haploinsufficient apolipoprotein-E-knockout (ATM^+/+ApoE^−/− or ATM^+/−ApoE^−/−) mice were treated with different dosages of chloroquine. Anti-CD25 antibody was used to deplete natural Tregs in ATM^+/+ApoE^−/− mice. The atherosclerotic burden in different groups of mice was comprehensively evaluated by H&E staining and Masson staining. The effect of chloroquine on the regulatory T cells (Tregs) was assessed in vivo and in vitro by flow cytometry and immunohistochemical staining. The expression of related proteins was detected by real-time polymerase chain reaction and western blotting.

Results In ATM^+/+ApoE^−/− mice, chloroquine alleviated atherosclerotic lesions, stabilized the plaque, and increased Treg counts in the atherosclerotic lesions and spleens. However, in ATM haploinsufficient mice (ATM^+/−ApoE^−/−), chloroquine no longer prevented atherosclerosis or impacted Treg counts. Abolishing Treg cells using an anti-CD25 antibody in vivo abrogated the atheroprotective effect of chloroquine. In vitro, chloroquine promoted the differentiation of Tregs from naïve T cells, which was accompanied by enhanced ATM/AMP-activated protein kinase (AMPK) activity and reduced downstream mammalian target of rapamycin (mTOR) activity.

Discussion These findings suggest that chloroquine ameliorates atherosclerosis and stabilizes plaque by modulating Tregs differentiation through the regulation of the ATM/AMPK/mTOR pathway.

Key words

antimalarial drugs - cardiovascular diseases - Tregs - ataxia-telangiectasia mutated

Publication History

Received: 15 May 2023
Received: 18 August 2023

Accepted: 23 October 2023

Article published online:
06 December 2023

• References

• 1 Du H, Shi Q, Song P. et al. Global burden attributable to high low-density lipoprotein-cholesterol from 1990 to 2019. Front Cardiovasc Med 2022; 9: 903126
• 2 Hao Q, Aertgeerts B, Guyatt G. et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: A clinical practice guideline with risk-stratified recommendations. BMJ 2022; 377: e069066
• 3 Hansson GK, Libby P, Schönbeck U. et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291
• 4 Wolf D, Ley K. Immunity and Inflammation in atherosclerosis. Circ Res 2019; 124: 315-327
• 5 Liu D, Li X, Zhang Y. et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: A systematic review and meta-analysis. Drug Des Devel Ther 2018; 12: 1685-1695
• 6 McGill JB, Johnson M, Hurst S. et al. Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness. Diabetol Metab Syndr 2019; 11: 61
• 7 Razani B, Feng C, Semenkovich CF. p53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J Lipid Res 2010; 51: 1738-1746
• 8 Schneider JG, Finck BN, Ren J. et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006; 4: 377-389
• 9 Matsuoka S, Ballif BA, Smogorzewska A. et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160-1166
• 10 Lacroix M, Riscal R, Arena G. et al. Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer. Mol Metab 2020; 33: 2-22
• 11 An N, Chen Y, Wang C. et al. Chloroquine autophagic inhibition rebalances Th17/Treg-mediated immunity and ameliorates systemic lupus erythematosus. Cell Physiol Biochem 2017; 44: 412-422
• 12 Park TY, Jang Y, Kim W. et al. Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases. Sci Rep 2019; 9: 15559
• 13 Thomé R, Moraes AS, Bombeiro AL. et al. Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. PLoS One 2013; 8: e65913
• 14 Genik PC, Bielefeldt-Ohmann H, Liu X. et al. Strain background determines lymphoma incidence in Atm knockout mice. Neoplasia 2014; 16: 129-136
• 15 Yang J, Guo Z, Liu X. et al. Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and physiologically based pharmacokinetic model. Front Pharmacol 2020; 11: 574720
• 16 Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol 2015; 35: 280-287
• 17 Meng X, Yang J, Dong M. et al. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol 2016; 13: 167-179
• 18 Ait-Oufella H, Salomon BL, Potteaux S. et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180
• 19 de Boer OJ, van der Meer JJ, Teeling P. et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007; 2: e779
• 20 Dietel B, Cicha I, Voskens CJ. et al. Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells. Atherosclerosis 2013; 230: 92-99
• 21 Liu ZD, Wang L, Lu FH. et al. Increased Th17 cell frequency concomitant with decreased Foxp3+Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflamm Res 2012; 61: 1155-1165
• 22 Rohm I, Atiskova Y, Drobnik S. et al. Decreased regulatory T cells in vulnerable atherosclerotic lesions: Imbalance between pro- and anti-inflammatory cells in atherosclerosis. Mediators Inflamm 2015; 2015: 364710
• 23 Meng X, Zhang K, Li J. et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med 2012; 18: 598-605
• 24 Tian Y, Chen T, Wu Y. et al. Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms. Cardiovasc Diabetol 2017; 16: 140
• 25 Piconi S, Parisotto S, Rizzardini G. et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118: 3263-3272
• 26 Mercer JR, Cheng KK, Figg N. et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res 2010; 107: 1021-1031
• 27 Swift M, Morrell D, Massey RB. et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836
• 28 Olsen JH, Hahnemann JM, Børresen-Dale AL. et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001; 93: 121-127
• 29 Alexander A, Cai SL, Kim J. et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 2010; 107: 4153-4158
• 30 Delgoffe GM, Kole TP, Zheng Y. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009; 30: 832-844
• 31 Sun IH, Oh MH, Zhao L. et al. mTOR complex 1 signaling regulates the generation and function of central and effector Foxp3(+) regulatory T cells. J Immunol 2018; 201: 481-492